Trials / Completed
CompletedNCT02657889
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 122 (actual)
- Sponsor
- Tesaro, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. (KEYNOTE-162)
Conditions
- Neoplasms
- Triple Negative Breast Cancer
- Ovarian Cancer
- Breast Cancer
- Metastatic Breast Cancer
- Advanced Breast Cancer
- Stage IV Breast Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | niraparib | |
| BIOLOGICAL | pembrolizumab |
Timeline
- Start date
- 2016-04-15
- Primary completion
- 2018-05-14
- Completion
- 2021-09-17
- First posted
- 2016-01-18
- Last updated
- 2022-12-01
- Results posted
- 2020-02-11
Locations
30 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02657889. Inclusion in this directory is not an endorsement.